Literature DB >> 7815346

Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.

S P Welch1, C Thomas, G S Patrick.   

Abstract

Dose-effect curves were generated for the cannabinoids [intracerebroventricularly (icv.)] and compared with those previously generated after administration intrathecally (i.t.). The ED50 values after administration of levonantradol, CP 55,940, delta 9-THC and delta 8-THC i.t. vs. icv. did not differ significantly. CP 56,667 was significantly more potent after icv. administration than i.t. administration, and was nearly 10 times more potent than CP 55,940 (icv.). CP 55,940 and CP 56,667, which did not produce greater than additive effects in combination with morphine when the drugs were administered i.t., shifted the morphine (icv.) dose-effect curve in a parallel manner nearly 10-fold after icv. administration. The antinociceptive effects of the cannabinoids (icv.) were not blocked by ICI 174,864 (20 micrograms/mouse), nor-BNI (70 micrograms/mouse) or naloxone (20 micrograms/mouse or 10 mg/kg s.c.). Pertussis toxin pretreatment i.t. for 7 days totally abolished the antinociception produced by the cannabinoids (icv. and i.t.). Pretreatment of the mice with forskolin (i.t.) or Cl-cAMP (10 micrograms/mouse i.t.), which produced no antinociception, significantly attenuated the antinociception produced by the delta 9-THC and CP 55,940. However, when administered icv., forskolin and Cl-cAMP produced antinociception, but did not block or produce greater than additive effects with the antinociception produced by the cannabinoids administered icv. The i.t. administration of calcium and calcium modulators failed to alter the antinociception produced by the i.t. administration of the cannabinoids. Conversely, calcium (icv.) blocked the antinociceptive effects of the cannabinoids. The AD50 values (+/- CL) for calcium-induced block of delta 9-THC, delta 8-THC and CP 55,940 were 215 (94-489), 176 (122-253) and 123 (81-186) nmol/mouse, respectively. omega-Conotoxin (1 micrograms/mouse icv.), which did not alter the antinociceptive effects of delta 9-THC, significantly reversed the calcium-induced blockade of delta 9-THC. Thapsigargin (icv.) blocked the antinociception produced by delta 9-THC and CP 55,940. Apamin, blocker calcium-gated potassium channels, produced a parallel rightward shift in the dose-effect curves of delta 9-THC, delta 8-THC and CP 55,940 (i.t.). However, apamin (5 ng/mouse icv.) failed to block icv. administered cannabinoids. Because acute administration of opiates/opioids have been shown to interact with Gi/o protein-coupled receptors, decrease calcium entry to and content of neurons, reduce cAMP levels and produce hyperpolarization of neurons via both ATP- and apamin-sensitive potassium channels, these three intracellular systems may be common points of interaction with the cannabinoids.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815346

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.

Authors:  Shao M Tham; James A Angus; Elizabeth M Tudor; Christine E Wright
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

2.  Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing.

Authors:  E Palazzos; V de Novellis; I Marabese; F Rossi; S Maione
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 3.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

4.  Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.

Authors:  Lisa K Brents; Sarah M Zimmerman; Amanda R Saffell; Paul L Prather; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2013-06-25       Impact factor: 4.030

5.  Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.

Authors:  M Mas-Nieto; B Pommier; E T Tzavara; A Caneparo; S Da Nascimento; G Le Fur; B P Roques; F Noble
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.

Authors:  Daniela Viganò; Tiziana Rubino; Angelo Vaccani; Silvia Bianchessi; Patrick Marmorato; Chiara Castiglioni; Daniela Parolaro
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

7.  Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.

Authors:  W J Martin; A G Hohmann; J M Walker
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

8.  The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids.

Authors:  Adrianne R Wilson-Poe; Edvinas Pocius; Melissa Herschbach; Michael M Morgan
Journal:  Pharmacol Biochem Behav       Date:  2012-10-10       Impact factor: 3.533

9.  Molecules Acting on CB1 Receptor and their Effects on Morphine Withdrawal In Vitro.

Authors:  Anna Capasso; Chiara Gallo
Journal:  Open Biochem J       Date:  2009-12-11

10.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.